Terms of Departure of Managing Director and CEO

Terms of Departure of Managing Director and CEO

Melbourne, Australia — 28/06/2013

CSL Limited (ASX:CSL) has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013.

“Dr McNamee’s leadership, drive and strategic vision over his 23 years as Managing Director and Chief Executive Officer were instrumental in building the Company into the exceptional global biopharmaceutical enterprise it is today. During this time, the Company has delivered exceptional growth in shareholder value. On behalf of the Board and all employees of CSL, I would like to thank Dr McNamee and to wish him every success in the future”, said CSL’s Chairman, Professor John Shine, AO.

Dr McNamee has worked collaboratively with the Board and his successor Mr Perreault over an extended period to ensure a smooth transition in the best interests of the Company. This includes Dr McNamee's agreement to remain available to the Company during the period 1 July to 15 October 2013.

The details of Dr McNamee’s benefits in connection with the cessation of his employment with the Company are set out in the Attachment.

While most aspects of Dr McNamee’s benefits have already been approved by the Board, the Board intends to seek shareholder approval at the 2013 Annual General Meeting for the provision of certain termination related benefits, which relate to certain long term incentives previously granted to Dr McNamee.

Download this release:
PDF icon Terms of Departure of Managing Director and CEO (0.30Mb)

For further information, please contact:

  Sharon McHale
  Senior Director Public Affairs
  CSL Limited
  Mobile: +614 0997 8314
  Email: sharon.mchale@csl.com.au
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 2818
  Email: mark.dehring@csl.com.au

© 2017 CSL Limited